Cancer therapy takes on autoimmune thyroid disease

NCT ID NCT07261345

Recruiting now Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tests a single infusion of genetically modified immune cells (CAR-T cells) in 4 people with refractory Graves' disease, a thyroid condition that doesn't respond well to standard medication. The cells target two proteins (CD19 and BCMA) to reset the immune system. The goal is to see if this approach can safely lead to remission, meaning normal thyroid function without needing daily drugs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: allogenic anti-CD19/BCMA CAR-T cells (RD06-05)
What this could lead to: If successful, this could offer a new treatment option for people with hard-to-control Graves' disease, potentially allowing them to stop long-term medication.
What could go wrong: This is a very early, small trial with only 4 participants. CAR-T therapy can cause serious side effects, and it's unknown if it will work for Graves' disease or provide lasting benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAVES DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Graves disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAVES DISEASE

Contacts and locations

Locations

Zhongshan Hospital Fudan University
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.